Author

Kimberly Dishman

Institution: Syndax Pharmaceuticals (United States)

Observed institution: Syndax Pharmaceuticals (United States)

OpenAlex ID: A5089340898

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

2022 · Ghayas C. Issa, Branko Cuglievan, et al. · Blood · 3

Works count: 1

Citation count: 3

H-index: 1

I10-index: